Search research articles
Contact Us
Filters
Showing results (261-270 of 290) with videos related to
Page
of 29
Sort By:
Cancer Science
|
July 22, 2024
Interim PET-guided ABVD or ABVD/escalated BEACOPP for newly diagnosed advanced-stage classic Hodgkin lymphoma (JCOG1305)
Shigeru Kusumoto, Wataru Munakata, Ryunosuke Machida, et al.
International Journal of Hematology
|
September 19, 2020
Pembrolizumab plus lenalidomide and dexamethasone in treatment-naive multiple myeloma (KEYNOTE-185): subgroup analysis in Japanese patients
Naoki Takezako, Hiroshi Kosugi, Morio Matsumoto, et al.
Annals of Hematology
|
March 2, 2023
Daratumumab plus bortezomib, cyclophosphamide, and dexamethasone in Asian patients with newly diagnosed AL amyloidosis: subgroup analysis of ANDROMEDA
Kenshi Suzuki, Ashutosh D Wechalekar, Kihyun Kim, et al.
Blood
|
March 1, 2024
ctDNA improves prognostic prediction for patients with relapsed/refractory MM receiving ixazomib, lenalidomide, and dexamethasone
Yasunori Kogure, Hiroshi Handa, Yuta Ito, et al.
British Journal of Haematology
|
June 26, 2020
Randomised phase II study to optimise melphalan, prednisolone, and bortezomib in untreated multiple myeloma (JCOG1105)
Dai Maruyama, Shinsuke Iida, Gakuto Ogawa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 9, 2025
BRUIN CLL-313: Randomized Phase III Trial of Pirtobrutinib Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Wojciech Jurczak, Michal Kwiatek, Jaroslaw Czyz, et al.
International Journal of Hematology
|
May 17, 2021
Expression of activated integrin β7 in multiple myeloma patients
Naoki Hosen, Satoshi Yoshihara, Hiroyuki Takamatsu, et al.
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology
|
December 13, 2016
Long-term follow-up results of a phase I/II study of melphalan, prednisolone and bortezomib in Japanese transplant-ineligible multiple myeloma patients (JPN-102)
Daisuke Ogiya, Hirohiko Shibayama, Eiji Nakatani, et al.
Cell Reports. Medicine
|
August 30, 2025
Inhibiting KRAS with CD47 and immune checkpoint overcomes intrinsic resistance to combined KRAS and immune checkpoint inhibitor therapy
Kentaro Hirade, Noritaka Tanaka, Taisuke Kajino, et al.
Blood Cancer Journal
|
February 15, 2020
Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma
Meletios A Dimopoulos, Andrzej J Jakubowiak, Philip L McCarthy, et al.
Page
of 29
Search research articles
Search
Showing results (261-270 of 290) with videos related to
Sort By:
Page
of 29
Cancer Science
|
July 22, 2024
Interim PET-guided ABVD or ABVD/escalated BEACOPP for newly diagnosed advanced-stage classic Hodgkin lymphoma (JCOG1305)
Shigeru Kusumoto, Wataru Munakata, Ryunosuke Machida, et al.
International Journal of Hematology
|
September 19, 2020
Pembrolizumab plus lenalidomide and dexamethasone in treatment-naive multiple myeloma (KEYNOTE-185): subgroup analysis in Japanese patients
Naoki Takezako, Hiroshi Kosugi, Morio Matsumoto, et al.
Annals of Hematology
|
March 2, 2023
Daratumumab plus bortezomib, cyclophosphamide, and dexamethasone in Asian patients with newly diagnosed AL amyloidosis: subgroup analysis of ANDROMEDA
Kenshi Suzuki, Ashutosh D Wechalekar, Kihyun Kim, et al.
Blood
|
March 1, 2024
ctDNA improves prognostic prediction for patients with relapsed/refractory MM receiving ixazomib, lenalidomide, and dexamethasone
Yasunori Kogure, Hiroshi Handa, Yuta Ito, et al.
British Journal of Haematology
|
June 26, 2020
Randomised phase II study to optimise melphalan, prednisolone, and bortezomib in untreated multiple myeloma (JCOG1105)
Dai Maruyama, Shinsuke Iida, Gakuto Ogawa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 9, 2025
BRUIN CLL-313: Randomized Phase III Trial of Pirtobrutinib Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Wojciech Jurczak, Michal Kwiatek, Jaroslaw Czyz, et al.
International Journal of Hematology
|
May 17, 2021
Expression of activated integrin β7 in multiple myeloma patients
Naoki Hosen, Satoshi Yoshihara, Hiroyuki Takamatsu, et al.
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology
|
December 13, 2016
Long-term follow-up results of a phase I/II study of melphalan, prednisolone and bortezomib in Japanese transplant-ineligible multiple myeloma patients (JPN-102)
Daisuke Ogiya, Hirohiko Shibayama, Eiji Nakatani, et al.
Cell Reports. Medicine
|
August 30, 2025
Inhibiting KRAS with CD47 and immune checkpoint overcomes intrinsic resistance to combined KRAS and immune checkpoint inhibitor therapy
Kentaro Hirade, Noritaka Tanaka, Taisuke Kajino, et al.
Blood Cancer Journal
|
February 15, 2020
Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma
Meletios A Dimopoulos, Andrzej J Jakubowiak, Philip L McCarthy, et al.
Page
of 29